1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Competitor Analysis: G-CSF and GM-CSF

Competitor Analysis: G-CSF and GM-CSF

  • April 2013
  • -
  • La Merie Publishing
  • -
  • 72 pages

Product description

The present Competitive Intelligence Report about G-CSF and GM-CSF product portfolios and R&D pipelines provides a competitor evaluation in the field of G-CSF & GM-CSF branded products in regulated markets and products in non-regulated markets, biosimilars (biogenerics, follow-on biologics) and next generation, longer acting products as of April 2013. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and non-regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2012. It lists the most advanced biosimilars of G-CSF and next generation G-CSF and of GM-CSF in regulated markets and non-regulated markets. In addition, the report lists company-specific product portfolios and R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing information on:
-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: G-CSF and GM-CSF
Table of Contents

2012 Sales of Branded G-CSF Products in Regulated Markets
1st Generation Branded G-CSF Products in Regulated Markets
Biosimilar 1st Generation G-CSF Products in Regulated Markets
Next Generation Branded G-CSF Products in Regulated Markets
Biosimilar Next Generation G-CSF Products in Regulated Markets
1st Generation G-CSF Products in Non-Regulated Markets:  India
1st Generation G-CSF Products in Non-Regulated Markets: China and Taiwan
1st Generation G-CSF Products in Non-Regulated Markets - Korea
1st Generation G-CSF Products in Non-Regulated Markets - Latin America
1st Generation G-CSF Products in Non-Regulated Markets: Other Territories
Next Generation G-CSF Products in Non-Regulated Markets
1st and Next Generation GM-CSF Products in Regulated Markets
1st and Next Generation GM-CSF Products in Non-Regulated Markets

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
G-CSF Inhibitors -Pipeline Insights, 2016

G-CSF Inhibitors -Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “G-CSF Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the G-CSF Inhibitors. The DelveInsight’s ...

Cancer Immunotherapy Market by Type, Application, End User - Global Forecast to 2021

Cancer Immunotherapy Market by Type, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, ...

Next-Generation Biologics Market 2016-2026: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

Next-Generation Biologics Market 2016-2026: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

  • $ 2508
  • Industry report
  • May 2016
  • by Visiongain

Report Details Emerging Biological Drugs – This New Study Reveals Selling Opportunities and Revenue Prospects to Help You Stay Ahead What is the future of biologics, especially new drug classes? Now ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.